Sangamo Q1 net loss $49.1M on revenue collapse to $0.5M from $158M; cash runway only into Q3 2024

SANGAMO THERAPEUTICS, INC

2024-Q1 EPS reported -$0.27 revenue$481,000

Net loss of $49.1M vs net income $21.1M YoY; diluted EPS -$0.27 vs +$0.12.
Revenue fell to $0.5M from $158M, driven by termination of Biogen/Novartis collaborations.
Cash $54.4M at March 31 (down from $81M); raised ~$24M gross via direct offering.
Pfizer expects BLA/MAA submission for hemophilia A gene therapy in early 2025 if mid-2024 pivotal readout positive.
Fabry gene therapy STAAR study fully dosed; seeking collaboration partner before registrational trial.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

SANGAMO THERAPEUTICS, INC reported financial results for the quarter ended March 31, 2024.

Period: the quarter ended March 31, 2024
Result: reported results

Exact text from the filing

On May 9, 2024, Sangamo Therapeutics, Inc. (“Sangamo”) issued a press release announcing its financial results for the quarter ended March 31, 2024 (the “Press Release”).

View on SEC.gov

1362 earnings releases filed in the last 30 days. Browse all earnings releases →

SANGAMO THERAPEUTICS, INC filing history →

Source: SEC EDGAR

accession 0001628280-24-022186

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.